Literature DB >> 2839557

Fluconazole penetration into cerebrospinal fluid in humans.

G Foulds1, D R Brennan, C Wajszczuk, A Catanzaro, D C Garg, W Knopf, M Rinaldi, D J Weidler.   

Abstract

One hour after intravenous doses of 50 mg/d fluconazole for 6 days or 100 mg/d for seven days to healthy subjects, the cerebrospinal fluid concentrations of fluconazole were 1.26 mg/L and 2.74 mg/L, respectively. These values were approximately 52% and 62% those of serum. Four patients with an initial clinical diagnosis of meningitis also had significant concentrations of fluconazole in the cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839557     DOI: 10.1002/j.1552-4604.1988.tb03159.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  35 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column.

Authors:  J E Wallace; S C Harris; J Gallegos; G Foulds; T J Chen; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography.

Authors:  J H Rex; L H Hanson; M A Amantea; D A Stevens; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

Authors:  T J Walsh; C Lester-McCully; M G Rinaldi; J E Wallace; F M Balis; J W Lee; P A Pizzo; D G Poplack
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug's Levels on Biophase?

Authors:  Izabel Almeida Alves; Keli Jaqueline Staudt; Fernando Olinto Carreño; Graziela de Araujo Lock; Carolina de Miranda Silva; Stela Maris Kuze Rates; Teresa Dalla Costa; Bibiana Verlindo De Araujo
Journal:  Pharm Res       Date:  2018-04-27       Impact factor: 4.200

7.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 8.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

9.  Influence of local radiotherapy on penetration of fluconazole into human saliva.

Authors:  J Oliary; M Tod; K Louchahi; O Petitjean; B Frachet; V Le Gros; N Brion
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.